Form 8-K

8-K — Axogen, Inc.

Accession: 0000805928-26-000051

Filed: 2026-04-28

Period: 2026-04-28

CIK: 0000805928

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — axgn-20260428.htm (Primary)

EX-99.1 — EX-99.1 Q1 2026 EARNINGS PRESS RELEASE (ex991axgnearningsreleaseda.htm)

EX-99.2 — EX-99.2 FIRST QUARTER FINANCIAL RESULTS PRESENTATION (ex992axgn_q1earningsrele.htm)

EX-99.3 — EX-99.3 - CORPORATE PRESENTATION DATED APRIL 2026 (ex993axgn_corporateprese.htm)

GRAPHIC — AXGN LOGO (axgn-20260428_g1.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 1 (ex992axgn_q1earningsrele001.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 2 (ex992axgn_q1earningsrele002.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 3 (ex992axgn_q1earningsrele003.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 4 (ex992axgn_q1earningsrele004.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 5 (ex992axgn_q1earningsrele005.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 6 (ex992axgn_q1earningsrele006.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 7 (ex992axgn_q1earningsrele007.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 8 (ex992axgn_q1earningsrele008.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 9 (ex992axgn_q1earningsrele009.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 10 (ex992axgn_q1earningsrele010.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 11 (ex992axgn_q1earningsrele011.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 12 (ex992axgn_q1earningsrele012.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 13 (ex992axgn_q1earningsrele013.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 14 (ex992axgn_q1earningsrele014.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 15 (ex992axgn_q1earningsrele015.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 16 (ex992axgn_q1earningsrele016.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 17 (ex992axgn_q1earningsrele017.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 18 (ex992axgn_q1earningsrele018.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 19 (ex992axgn_q1earningsrele019.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 20 (ex992axgn_q1earningsrele020.jpg)

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 21 (ex992axgn_q1earningsrele021.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 1 (ex993axgn_corporateprese001.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 2 (ex993axgn_corporateprese002.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 3 (ex993axgn_corporateprese003.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 4 (ex993axgn_corporateprese004.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 5 (ex993axgn_corporateprese005.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 6 (ex993axgn_corporateprese006.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 7 (ex993axgn_corporateprese007.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 8 (ex993axgn_corporateprese008.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 9 (ex993axgn_corporateprese009.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 10 (ex993axgn_corporateprese010.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 11 (ex993axgn_corporateprese011.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 12 (ex993axgn_corporateprese012.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 13 (ex993axgn_corporateprese013.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 14 (ex993axgn_corporateprese014.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 15 (ex993axgn_corporateprese015.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 16 (ex993axgn_corporateprese016.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 17 (ex993axgn_corporateprese017.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 18 (ex993axgn_corporateprese018.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 19 (ex993axgn_corporateprese019.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 20 (ex993axgn_corporateprese020.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 21 (ex993axgn_corporateprese021.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 22 (ex993axgn_corporateprese022.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 23 (ex993axgn_corporateprese023.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 24 (ex993axgn_corporateprese024.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 25 (ex993axgn_corporateprese025.jpg)

GRAPHIC — CORPORATE PRESENTATION PAGE 26 (ex993axgn_corporateprese026.jpg)

GRAPHIC — AXGN LOGO (image_0a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: axgn-20260428.htm · Sequence: 1

axgn-20260428

0000805928false00008059282026-04-282026-04-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2026

AXOGEN, INC.

(Exact Name of Registrant as Specified in Charter)

Minnesota

(State or Other Jurisdiction of

Incorporation or Organization)

001-36046

(Commission File Number)

41-1301878

(I.R.S. Employer Identification No.)

13631 Progress Boulevard, Suite 400 Alachua, Florida

(Address of principal executive offices)

32615

(Zip Code)

(386) 462-6800

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of exchange on which registered

Common Stock, $0.01 par value AXGN The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On April 28, 2026, Axogen, Inc. (the “Company”) issued a press release announcing its first quarter 2026 financial results. A copy of the press release is furnished as Exhibit 99.1.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 7.01 Regulation FD Disclosure

On April 28, 2026, the Company posted a first quarter 2026 financial results presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the financial results presentation from time to time in conversation with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.2.

On April 28, 2026, the Company posted an updated corporate presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the corporate presentation from time to time in conversation with analysts, investors, and others. A copy of the corporate presentation is furnished as Exhibit 99.3.

The information in this Item 7.01, including Exhibits 99.2 and 99.3, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Axogen Inc. Earnings Press Release, dated April 28, 2026

99.2

Axogen Inc. First Quarter Financial Results Presentation, dated April 28, 2026

99.3

Axogen, Inc. Corporate Presentation, dated April 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AXOGEN, INC.

Dated: April 28, 2026

By: /s/ Marc Began

Marc Began

Executive Vice President, General Counsel and Chief Compliance Officer

EX-99.1 — EX-99.1 Q1 2026 EARNINGS PRESS RELEASE

EX-99.1

Filename: ex991axgnearningsreleaseda.htm · Sequence: 2

Document

Exhibit 99.1

Axogen, Inc. Reports First Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million

ALACHUA and TAMPA, FL – April 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026.

First Quarter Financial Results

•First quarter 2026 revenue was $61.5 million, a 26.6% increase compared to first quarter 2025 revenue of $48.6 million.

•Gross margin was 75.2% for the first quarter of 2026, compared to 71.9% in the first quarter of 2025.

•Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, compared to $3.8 million, or $0.08 per share for the first quarter of 2025.

•Adjusted net income was $4.1 million for the first quarter of 2026, or $0.07 per share, compared to an adjusted net loss of $0.9 million, or $0.02 per share for the first quarter 2025.

•Adjusted EBITDA was $5.7 million for the first quarter of 2026, compared to $2.9 million for the first quarter of 2025.

•As of March 31, 2026, cash and cash equivalents, restricted cash, and investments was $103.6 million, as compared to $45.5 million as of December 31, 2025, an increase of $58.1 million.

“We are pleased with our first-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities,” said Michael Dale, President and CEO of Axogen, Inc. “We delivered strong growth across all of our target markets, reinforcing the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our financial guidance and continue advancing our strategic objectives for 2026.”

Summary of Business Highlights

•First quarter 2026 revenue growth was broad-based, including double-digit growth in all markets, which includes Extremities, Oral Maxillofacial & Head and Neck, and Breast.

•Received positive coverage decisions from Cigna and Elevance Health, two of the nation’s largest commercial insurers.

•Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement 40% year-over-year to $8,965 for hospital outpatient and 35% to $6,157 for ASC-based procedures.

•On January 23, 2026, Axogen closed an upsized public offering with the sale of 4.6 million shares of common stock, yielding net proceeds of $133.3 million. From these net proceeds, $69.7 million were used

to fully repay and terminate our Oberland loan facility on January 28, 2026. Remaining funds are available for working capital, capital expenditures, and other general corporate purposes.

2026 Financial Guidance

We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%. Additionally, we expect to be free cash flow positive for the full-year.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release and accompanying earnings call contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements under the heading “2026 Financial Guidance” and statements regarding our business model optimization plans; market development strategies and objectives; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our ability to sustain growth, operate profitably, generate positive cash flows, and fund our market development initiatives; and the anticipated use of proceeds from our recent public offering. These statements are based on management’s current expectations and estimates of trends and economic factors in the markets in which we are active. Words such as “expects,” “anticipates,” “objectives,” “targets,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, “Risk Factors,” in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they

are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net Loss and Net Loss Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.

These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Contact:

Axogen, Inc.

InvestorRelations@axogeninc.com

Axogen, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

March 31,

2026 December 31,

2025

Assets

Current assets:

Cash and cash equivalents $ 82,654  $ 35,548

Restricted cash 2,000  4,000

Investments 18,947  5,980

Accounts receivable, net of allowance for doubtful accounts of $822 and $948, respectively

28,313  26,169

Inventory 46,074  42,373

Prepaid expenses and other assets 6,720  6,352

Total current assets 184,708  120,422

Property and equipment, net 83,038  81,783

Operating lease right-of-use assets 14,280  12,732

Intangible assets, net 7,270  6,750

Other assets 192  —

Total assets $ 289,488  $ 221,687

Liabilities and shareholders’ equity

Current liabilities:

Accounts payable and accrued expenses $ 23,898  $ 21,184

Current maturities of long-term lease obligations 2,115  2,372

Total current liabilities 26,013  23,556

Long-term debt, net of debt discount and financing fees —  48,387

Long-term lease obligations 18,527  16,870

Debt derivative liabilities —  3,886

Other long-term liabilities 140  141

Total liabilities 44,680  92,840

Shareholders’ equity:

Common stock, $0.01 par value per share; 100,000,000 shares authorized; 53,153,471 and 47,199,797 shares issued and outstanding, respectively

532  472

Additional paid-in capital 570,823  435,338

Accumulated deficit (326,547) (306,963)

Total shareholders’ equity 244,808  128,847

Total liabilities and shareholders’ equity $ 289,488  $ 221,687

Axogen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

Three Months Ended

March 31, 2026 March 31, 2025

Revenues $ 61,457  $ 48,560

Cost of goods sold 15,268  13,627

Gross profit 46,189  34,933

Costs and expenses:

Sales and marketing 28,633  21,045

Research and development 7,517  6,091

General and administrative 12,871  9,458

Total costs and expenses 49,021  36,594

Loss from operations (2,832) (1,661)

Other income (expense):

Investment income 768  272

Interest expense (694) (2,250)

Loss on extinguishment of debt (16,849) —

Change in fair value of debt derivative liabilities —  (158)

Other income (expense), net 23  (37)

Total other expense, net (16,752) (2,173)

Net loss $ (19,584) $ (3,834)

Weighted average common shares outstanding — basic 51,591,504  45,204,076

Weighted average common shares outstanding — diluted 51,591,504  45,204,076

Net loss per common share — basic $ (0.38) $ (0.08)

Net loss per common share — diluted $ (0.38) $ (0.08)

Axogen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Three Months Ended

March 31, 2026 March 31, 2025

Cash flows from operating activities:

Net loss $ (19,584) $ (3,834)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Depreciation 1,604  1,728

Amortization of right-of-use assets 420  87

Amortization of intangible assets 101  67

Amortization of debt discount and deferred financing fees 68  220

(Recovery of) provision for bad debts (120) 187

Change in fair value of debt derivative liabilities —  158

Investment losses (gains), net 33  (45)

Loss on extinguishment of debt 16,849  —

Stock-based compensation expense 6,843  2,909

Change in operating assets and liabilities:

Accounts receivable (2,024) (2,377)

Inventory (3,701) (2,321)

Prepaid expenses and other assets (368) (489)

Other assets (192) —

Accounts payable and accrued expenses 2,198  (9,079)

Operating lease obligations (559) (452)

Cash paid for interest portion of financing lease obligations (2) (1)

Other long-term liabilities (1) 63

Net cash provided by (used in) operating activities 1,565  (13,179)

Cash flows from investing activities:

Purchase of property and equipment (2,789) (256)

Purchase of investments (19,000) —

Proceeds from sale of investments 6,000  2,000

Cash payments for intangible assets (175) (405)

Net cash (used in) provided by investing activities (15,964) 1,339

Cash flows from financing activities:

Proceeds from issuance of common stock 134,044  —

Payment of stock issuance costs (792) —

Repayment of long-term debt (48,585) —

Fees paid to lender related to debt extinguishment (20,498) —

Fees paid to third parties related to debt extinguishment (107) —

Payments of employee tax withholding on vested stock awards (8,776) —

Cash paid for debt portion of financing lease obligations (7) (1)

Proceeds from exercise of stock options 4,226  2,383

Net cash provided by financing activities 59,505  2,382

Net increase (decrease) in cash and cash equivalents, and restricted cash 45,106  (9,458)

Cash and cash equivalents, and restricted cash, beginning of period 39,548  33,554

Cash and cash equivalents, and restricted cash, end of period $ 84,654  $ 24,096

Axogen, Inc.

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(unaudited)

(in thousands, except share amounts)

Common Stock Additional Paid-in

Capital Accumulated

Deficit Total Shareholders'

Equity

Shares Amount

Three Months Ended March 31, 2026

Balance at December 31, 2025 47,199,797  $ 472  $ 435,338  $ (306,963) $ 128,847

Net loss —  —  —  (19,584) (19,584)

Issuance of common shares 4,600,000  46  133,206  —  133,252

Stock-based compensation —  —  6,843  —  6,843

Issuance of restricted and performance stock units, net of shares withheld for withholding taxes 985,796  10  (8,786) —  (8,776)

Exercise of stock options 367,878  4  4,222  —  4,226

Balance at March 31, 2026 53,153,471  $ 532  $ 570,823  $ (326,547) $ 244,808

Three Months Ended March 31, 2025

Balance at December 31, 2024 44,148,836  $ 441  $ 394,726  $ (291,260) $ 103,907

Net loss —  —  —  (3,834) (3,834)

Stock-based compensation —  —  2,909  —  2,909

Issuance of restricted and performance stock units 1,105,214  11  (11) —  —

Exercise of stock options 258,573  3  2,380  —  2,383

Balance at March 31, 2025 45,512,623  $ 455  $ 400,004  $ (295,094) $ 105,365

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

EBITDA & Adjusted EBITDA Three Months Ended

March 31, 2026 March 31, 2025

Net loss $ (19,584) $ (3,834)

Depreciation and amortization expense 1,706  1,795

Investment income (768) (272)

Income tax (benefit) expense (33) 29

Interest expense 694  2,250

EBITDA - non-GAAP $ (17,985) $ (32)

EBITDA margin - non-GAAP (29.3) % (0.1) %

Non-cash stock-based compensation expense 6,843  2,909

Loss on extinguishment of debt 16,849  —

Adjusted EBITDA - non-GAAP $ 5,707  $ 2,877

Adjusted EBITDA margin - non-GAAP 9.3  % 5.9  %

Adjusted Net Income Three Months Ended March 31, 2026

GAAP Results Non-cash Stock-based Compensation Expense Loss on Extinguishment of Debt

Dilutive Shares Impact(1)

Adjusted Results

Revenues $ 61,457  $ —  $ —  $ 61,457

Cost of goods sold 15,268  (919) —  14,349

Gross profit 46,189  919  —  47,108

Costs and expenses:

Sales and marketing 28,633  (1,558) —  27,075

Research and development 7,517  (1,419) —  6,098

General and administrative 12,871  (2,947) —  9,924

Total costs and expenses 49,021  (5,924) —  43,097

(Loss) income from operations (2,832) 6,843  —  4,011

Other income (expense):

Investment income 768  —  —  768

Interest expense (694) —  —  (694)

Loss on extinguishment of debt (16,849) —  16,849  —

Other income, net 23  —  —  23

Total other (expense) income, net (16,752) —  16,849  97

Net (loss) income $ (19,584) $ 6,843  $ 16,849  $ 4,108

Weighted average common shares outstanding - diluted 51,591,504  51,591,504  51,591,504  5,183,717  56,775,221

Net (loss) income per common share - diluted $ (0.38) $ 0.13  $ 0.33  $ (0.01) $ 0.07

__________

(1)Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

Adjusted Net Income Three Months Ended March 31, 2025 Three Months Ended June 30, 2025 Three Months Ended September 30, 2025 Three Months Ended December 31, 2025

GAAP Results Non-cash Stock-based Compensation Expense Adjusted Results GAAP Results Non-cash Stock-based Compensation Expense Adjusted Results GAAP Results Non-cash Stock-based Compensation Expense Adjusted Results GAAP Results Non-cash Stock-based Compensation Expense

Adjusted Results (1)

Revenues $ 48,560  $ —  $ 48,560  $ 56,662  $ —  $ 56,662  $ 60,082  $ —  $ 60,082  $ 59,904  $ —  $ 59,904

Cost of goods sold 13,627  10  13,637  14,644  (709) 13,935  14,089  (706) 13,383  15,495  (2,274) 13,221

Gross profit 34,933  (10) 34,923  42,018  709  42,727  45,993  706  46,699  44,409  2,274  46,683

Costs and expenses:

Sales and marketing 21,045  (584) 20,461  23,804  (1,314) 22,490  25,680  (1,524) 24,156  27,211  (2,939) 24,272

Research and development 6,091  (720) 5,371  6,853  (1,030) 5,823  7,565  (1,047) 6,518  12,376  (6,052) 6,324

General and administrative 9,458  (1,615) 7,843  9,689  (2,115) 7,574  10,836  (2,147) 8,689  14,594  (5,346) 9,248

Total costs and expenses 36,594  (2,919) 33,675  40,346  (4,459) 35,887  44,081  (4,718) 39,363  54,181  (14,337) 39,844

(Loss) income from operations (1,661) 2,909  1,248  1,672  5,168  6,840  1,912  5,424  7,336  (9,772) 16,611  6,839

Other income (expense):

Investment income 272  —  272  225  —  225  319  —  319  352  —  352

Interest expense (2,250) —  (2,250) (1,977) —  (1,977) (1,757) —  (1,757) (1,718) —  (1,718)

Change in fair value of debt derivative liabilities (158) —  (158) 480  —  480  209  —  209  (2,018) —  (2,018)

Other (expense) income, net (37) —  (37) 179  —  179  25  —  25  —  —  —

Total other expense, net (2,173) —  (2,173) (1,093) —  (1,093) (1,204) —  (1,204) (3,384) —  (3,384)

Net (loss) income $ (3,834) $ 2,909  $ (925) $ 579  $ 5,168  $ 5,747  $ 708  $ 5,424  $ 6,132  $ (13,156) $ 16,611  $ 3,455

Weighted average common shares outstanding - diluted 45,204,076  45,204,076  45,204,076  47,980,830  47,980,830  47,980,830  49,088,436  49,088,436  49,088,436  46,929,309  46,929,309  52,230,508

Net (loss) income per common share - diluted $ (0.08) $ 0.06  $ (0.02) $ 0.01  $ 0.11  $ 0.12  $ 0.01  $ 0.11  $ 0.12  $ (0.28) $ 0.35  $ 0.07

__________

(1)Due to a GAAP net loss during the three months ended December 31, 2025, 5,301,199 antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP. The inclusion of these shares decreased adjusted Net income per common share by less than $0.01.

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

Adjusted Net Income Twelve Months Ended December 31, 2025

GAAP Results Non-cash Stock-based Compensation Expense

Dilutive Shares Impact(1)

Adjusted Results

Revenues $ 225,208  $ —  $ 225,208

Cost of goods sold 57,855  (3,680) 54,175

Gross profit 167,353  3,680  171,033

Costs and expenses:

Sales and marketing 97,740  (6,361) 91,379

Research and development 32,885  (8,848) 24,037

General and administrative 44,577  (11,223) 33,354

Total costs and expenses 175,202  (26,432) 148,770

(Loss) income from operations (7,849) 30,112  22,263

Other income (expense):

Investment income 1,168  —  1,168

Interest expense (7,702) —  (7,702)

Change in fair value of debt derivative liabilities (1,487) —  (1,487)

Other income, net 167  —  167

Total other expense, net (7,854) —  (7,854)

Net (loss) income $ (15,703) $ 30,112  $ 14,409

Weighted average common shares outstanding - diluted 46,050,266  46,050,266  3,761,920  49,812,186

Net (loss) income per common share - diluted $ (0.34) $ 0.65  $ (0.02) $ 0.29

__________

(1)Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Free Cash Flow Three Months Ended

March 31, 2026 March 31, 2025

Net cash provided by (used in) operating activities $ 1,565  $ (13,179)

Purchase of property and equipment (2,789) (256)

Cash payments for intangible assets (175) (405)

Free cash flow $ (1,399) $ (13,840)

EX-99.2 — EX-99.2 FIRST QUARTER FINANCIAL RESULTS PRESENTATION

EX-99.2

Filename: ex992axgn_q1earningsrele.htm · Sequence: 3

ex992axgn_q1earningsrele

Q1 2026 Financial Results April 28th, 2026 April 2026

Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “objectives,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements related to: clinical development activities, including expansion into prostate applications; commercial growth initiatives, including planned expansion of breast and extremities sales specialists; market development opportunities; expectations regarding disciplined, profitable growth and margin improvement; financial guidance and outlook for 2026, including projected revenue growth, free cash flow, gross margins, and other operating performance metrics; and statements regarding our training and education initiatives, reimbursement and market access efforts, and research and development activities. Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, risks related to global supply chain conditions, inflationary pressures, hospital staffing challenges, product development and product potential, clinical enrollment timing and outcomes, regulatory processes and approvals, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, geopolitical and macroeconomic conditions, including armed conflicts and government actions or policies that may affect our business, tax position, or regulatory processes, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” of our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. 2 About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net Loss and Net Loss Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non- GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

3 Q1 2026 Business Highlights and 2026 Goals Michael Dale President and Chief Executive Officer

Agenda 4 1.Q1 2026 Business Highlights Michael Dale, President and Chief Executive Officer 2.Q1 2026 Financials and 2026 Guidance Lindsey Hartley, Chief Financial Officer 3.Q&A Michael Dale, Lindsey Hartley, Jens Kemp, Chief Marketing Officer Rick Ditto, VP Global Health Economics, Reimbursement & Policy

Strategic Priorities 01 Growth 15–20% Revenue CAGR + Operating Leverage 02 Market Development Elective & Planned Procedures + Prostate market development 03 Commercial Expansion Infrastructure and Sales Force expansion 04 Commercial Excellence Continuous business model and customer creation process optimization by market 05 Standard Of Care Clinical evidence generation for societal support, standard of care & coverage requirements 06 Innovation Product development to drive better benefit versus risk profiles in nerve care 5

Large and Underserved $5.6B* US Nerve Care Opportunity 6 Traumatic Nerve Injuries  Transected Nerves  Non-Transected Nerve Injuries  Brachial Plexus Nerve Injuries Breast Procedures  Autologous Flap Procedures  Implant based reconstruction Robotic Assisted Radical Prostatectomies  Nerve Sparing  Unilateral Nerve Sparing  Non-Nerve Sparing Extremities $2.9bn Estimated TAM* OMF/H&N $1.2bn Breast $677m Prostate $754m TAM Included Procedures Chronic Nerve Injuries  Carpal & Cubital Tunnel Revision  Neuroma & Tumor Excisions  Lower Extremity Neuropathy OMF/H&N Procedures  Mandibular Resection  Iatrogenic Injuries  Orthognathic Surgery  Parotidectomy  Thyroidectomy  Corneal Neurotization  Radical neck dissection 1. National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables 2.Axogen Data on File, 3. AcuityMD 4. 2022 ASPS Procedural Statistics Release Inclusion Comments o All traumatic transected nerve injuries o All traumatic non-transected nerve injuries o Revision decompression in upper extremities o Lower extremity decompressions, Morton’s neuroma excision, and addressable amputations o Benign and malignant mandible resections o H&N procedures * TAM = Addressable procedures X Algorithm utilization X Product ASP o DEIP flaps and other neurotizable flaps o Direct to implant, <400cc o All robotic assisted radical prostatectomies o Procedure split estimated: 60% Nerve sparing, 20% unilateral nerve sparing and 20% non nerve sparing More than 1.5 million peripheral nerve injuries a year require treatment in Axogen focus markets1,2,3,4

7 Strategic Priorities Q1 2026 Business Highlights 01 Growth 15–20% Revenue CAGR + Operating Leverage Q1 Revenue $61.5M, +26.6% YoY Capital Structure Raised $133.3M; retired $69.7M term loan 2026 Target Disciplined profitable growth; improving margins 02 Market Development Elective & Planned + Prostate Extremities Solid traumatic & chronic growth; most mature market OMF / H&N High double-digit growth; quality-of-life recognition growing Breast Fast-growing; accelerating Resensation adoption Prostate 10+ active clinical sites 2026 Prostate Meaningful clinical signals expected in 2H 2026 03 Commercial Expansion Infrastructure + Sales Force Growth Breast 26 reps, 3 regional directors Extremities 120 reps, 15 regional directors OMF / H&N 4 field-based market development managers Prostate 3 clinical development managers and 1 director 2026 Breast / Ext. Grow to ~30 breast reps; ~130 extremity reps 7 Q1 Adjusted EBITDA* $5.7M, +3.4 pp as a percent of revenue YoY

8 Strategic Priorities Q1 2026 Business Highlights 2026 2026 2026 04 Commercial Excellence HiPo Accounts, Productivity & Education HiPo Revenue 48% of growth from HiPo accounts Productivity +21% avg. HiPo account productivity Active Accounts 681 HiPo accounts; added 70+ active surgeons Education Surgeon training across all markets on track to plan HiPo & Training 60% growth from HiPo; +18% productivity; add 100+ active surgeons. 21 professional education programs; train 300 surgeons and 75 surgeon pairs. 05 Standard Of Care Evidence, Coverage & Avance® FDA BLA Avance® First & only FDA-approved biologic for peripheral nerve repair and 12 years of U.S. biologics exclusivity period Societies AAHS & ASRM recognize allograft as standard of care (1) Coverage Positive coverage decisions from Cigna and Elevance received Payer & Coverage Pursue near-universal US coverage (est. 2H 2028) 06 Innovation R&D + Therapeutic Reconstruction Program Updates Detailed updates on individual R&D programs in 2H 2026 Ease of Coaptation R&D focused on faster, more consistent nerve coaptation Chronic Injuries Advancing non-transected and chronic nerve repair solutions Therapeutic Reconstruction Next-gen technologies to improve nerve regeneration Clinical Studies Breast & mixed/motor nerve studies on track to plan 8 (1) The American Association of Hand Surgery (“AAHS”) and the American Society for Reconstructive Microsurgery (“ASRM”) released official position statements recognizing nerve allograft as a standard medical practice option for the treatment of peripheral nerve defects during the third quarter of 2025.

9 Q1 Financials and 2026 Guidance Discussion Lindsey Hartley Chief Financial Officer

Q1 2026 Financial Performance 10 +3.3pp +26.6%

Q1 2026 Financial Performance 11 Q1 2026 Q1 2025 Revenues $61.5 $48.6 Sales and Marketing Expenses $28.6 $21.0 Research and Development Expenses 7.5 6.1 General and Administrative Expenses 12.9 9.5 Total Costs and Expenses $49.0 $36.6 YoY Change % 34.0% Change as a % Of Revenue (1) 4.5% (1) Non-cash stock-based compensation expense negatively impacted Q1 operating margin by approximately 3.5 percentage points. ($ in millions)

12 Q1 2026 Q1 2025 Net Loss $(19.6) $(3.8) Diluted EPS $(0.38) $(0.08) Adjusted Net Income (Loss)* $4.1 $(0.9) Adjusted Diluted EPS* $0.07 $(0.02) Adjusted EBITDA* $5.7 $2.9 Adjusted EBITDA Margin* 9.3% 5.9% Free Cash Flow* $(1.4) $(13.8) Q1 2026 Financial Performance ($ in millions, except per share data) * See non-GAAP reconciliations included in Appendix.

Guidance for the Full-Year 2026 13 Free cash flow* positiveGross margin of 74% to 76%Revenue growth of at least 20% or $270 million * See non-GAAP reconciliations included in Appendix.

President and Chief Executive Officer Michael Dale Chief Marketing Officer Jens Kemp VP, Global Health Economics, Reimbursement & Policy Rick Ditto 14 Chief Financial Officer Lindsey Hartley Q&A

Thank you © 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation.Mat #

Appendix 16

17 Non-GAAP Reconciliations - EBITDA & Adjusted EBITDA: Three Months Ended March 31, (in thousands)​ 2026 2025 Net loss $ (19,584) $ (3,834) Depreciation and amortization expense 1,706 1,795 Investment income (768) (272) Income tax (benefit) expense (33) 29 Interest expense 694 2,250 EBITDA - non-GAAP $ (17,985) $ (32) EBITDA margin - non-GAAP (29.3)% (0.1)% Non-cash stock-based compensation expense 6,843 2,909 Loss on extinguishment of debt 16,849 — Adjusted EBITDA - non-GAAP $ 5,707 $ 2,877 Adjusted EBITDA margin - non-GAAP 9.3 % 5.9 %

18 ___________ (1) Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

20 Non-GAAP Reconciliation - Free Cash Flow: Three Months Ended March 31, (in thousands)​ 2026 2025 Net cash provided by (used in) operating activities $ 1,565 $ (13,179) Purchase of property and equipment (2,789) (256) Cash payments for intangible assets (175) (405) Free cash flow $ (1,399) $ (13,840)

© 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation.

EX-99.3 — EX-99.3 - CORPORATE PRESENTATION DATED APRIL 2026

EX-99.3

Filename: ex993axgn_corporateprese.htm · Sequence: 4

ex993axgn_corporateprese

Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. April 2026

Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “objectives,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements related to: clinical development activities, including expansion into prostate applications; commercial growth initiatives, including planned expansion of breast and extremities sales specialists; market development opportunities; expectations regarding disciplined, profitable growth and margin improvement; financial guidance and outlook for 2026, including, but not limited to, projected revenue, growth, free cash flows, gross margins, and other operating performance and financial metrics; and statements regarding our training and education initiatives, reimbursement and market access efforts, and research and development activities. Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, risks related to global supply chain conditions, inflationary pressures, hospital staffing challenges, product development and product potential, clinical enrollment timing and outcomes, regulatory processes and approvals, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, geopolitical and macroeconomic conditions, including armed conflicts and government actions or policies that may affect our business, tax position, or regulatory processes, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” of our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. 2 About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and litigation related costs, and Adjusted EBITDA margin. We also use the Free Cash Flow metric, which corresponds to the net cash provided by (used in) operating activities less cash used for purchases of property and equipment and intangible assets. These non- GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.

3 To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. Our Mission

4 Large and Underserved $5.6B US Nerve Care Opportunity More than 1.5 million peripheral nerve injuries a year require treatment in Axogen focus markets1,2,3,7 Extremities Market Every year patients suffer from 700,000 Traumatic Nerve Injuries and more than 370,000 Chronic nerve injuries.1,2,3 Breast Reconstruction 1 of 8 women diagnosed with breast cancer. 80% of women experience pain, numbness or both after breast cancer surgery.4 Oral, Maxillofacial & Head & Neck Nerve damage caused by Oral Maxillofacial and H&N surgery is common and can result in loss of sensation and chronic pain. Prostate Surgery $1.2B$677M $754M Nerve injuries have a significant impact on patient’s quality of life… 1 of 8 men diagnosed with prostate cancer. 25-90% experience Incontinence and Erectile Dysfunction (ED) Post robotic prostatectomy.5,6 $2.9B 1. National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables 2. Axogen Data on File, 3. Acuity MD, 4. Flowers et al., Pain Rep, 2021, 6(4):e976, 5. American Cancer Society, 2025, 6. Tal R, et al. J Sex Med. 2009;6(9):2538–2546. 7. 2022 ASPS Procedural Statistics Release

Common Types and Causes of Peripheral Nerve Injury Cut or Laceration Compression Stretching Neuroma Trauma Trauma that leads to damaged nerves Severe Cuts, Falling Though Glass, Compression, Gunshot Wound, Blunt Trauma Amputation Stump pain associated with nerve damage has been reported in over 68% of amputees1 Sensitivity to Touch, Residual Limb Pain, Burning Pain Surgery Nerves that have been cut, compressed or stretched during surgery Mastectomy, Laparoscopy, Tumor Resection, Wrist or Knee Arthroscopy, Hip or Knee Arthroplasty 51. Ephraim et al.,Arch Phys Med Rehabil, 2005;86:1910–1919

The Axogen Nerve Repair Algorithm 6 Connection Protection Termination

Avance® is the First Approved Biologic Treatment for Repair of Nerve Discontinuities i l i reat ent for e air of Provides structural and biochemical cues for axonal regeneration 7 Native Nerve in adult and pediatric patients aged one month and older Laminin lining the endoneurial tubes has been shown in in vitro assays and animal studies to be bioactive by supporting Schwann cell migration, axon growth cone interactions, and neurite extension. Proprietary quality assays verify structural integrity & potency See Full Prescribing Information at www.avancenervegraft.com

8 Our Key Market Development Opportunities Care guidelines and standardized treatment algorithms are lagging and to be developed for certain care pathways Nerve Care is Not an Expected Standard of Care Low patient and surgeon awareness of treatment options Awareness of Treatment Options Approximately 60% of nerve injuries go undiagnosed prior to patient discharge1 Inefficient Patient Referral and Care Pathways 14% of commercial lives remain uncovered2,3Coverage & Payment 1. Padovano et al., Hand (NY), 2022, 17(4):615–623, 2. Policy Reporter online portal for medical policy information [Dec 2025, 3. Health plan enrollment data provided by Managed Markets Insight & Technology, LLC [Sept 2025]

9 2025-2028 Strategic Plan Priorities Commercial infrastructure and salesforce expansion Continuous business model and customer creation process optimization by market Product development to drive better benefit versus risk profiles in nerve care Elective and planned procedure focus Prostate market development CAGR 15 - 20% Commercial Excellence Commercial Expansion Innovation MarketsGrowth Level 1 clinical evidence generation for societal support, standard of care & coverage requirements Standard of Care

Uniquely Positioned to Lead in Nerve Repair Avance® (acellular nerve allograft-arwx) is the only FDA approved biologic nerve scaffold for treating peripheral nerve discontinuities Axoguard® and Avive+ products for use across Axogen nerve repair algorithm 17 years of experience and 275,000+ patients treated 350+ clinical and scientific publications supporting our nerve repair algorithm A valued educational partner committed to clinical science and innovation Trusted partner to 6,500+ surgeons Established access in more than 2,700 hospitals and outpatient centers, supported by the largest direct sales channel Technology Expertise Access 10

Elevating Nerve IQ 11 75% of hand fellows trained 13 Professional education programs across our markets with more than 225 surgeons trained 117 Regional programs helping to enhance the micro surgical skills of surgeons Surgeons trained on Axogen’s nerve repair algorithm 55 Faculty educational partners of leading nerve repair thought leaders 2025 ACTIVITY 1,400 Education & Training are Key to Market Development

Societal Support Avance is supported as standard medical practice by major societies and Axogen has strong KOL relationships that drive advocacy, portfolio adoption and innovation POSITIONED TO WIN Preference for allograft increasing for all gap lengths1 Comparable procedural cost to Autograft2 Allograft supported as standard medical practice by two major societies Educational Leadership Axogen is a trusted educational partner providing hand surgeons with the microsurgical skills to effectively repair nerves utilizing our portfolio Comprehensive Portfolio & Access We offer the most comprehensive portfolio of nerve repair solutions, which is widely approved and accessible in US hospital systems Focused Direct Sales Channel Dedicated sales channel for nerve repair, which ensures focus and support for nerve surgeons Clinical & Health Economic Value Avance is approved as a biologic, backed by level 1 clinical evidence and health economic value proposition versus autograft Extremities 41.0% 24.1% 18.2% 16.7% Allograft Autograft Conduit Direct repair 2024 Preferred Nerve Repair Solution for >2cm Gap 121. Axogen. Data on File., 2. Lans J, et al. Plast Reconstr Surg. 2023;151(5):814e–827e.

POSITIONED TO WIN Growing body of evidence supporting the benefits or nerve reconstruction Grow presence in H&N oncologic procedures Opportunity to build patient and surgeon awareness of the patient QoL impact Expand educational capacity & programs Societal Support OMF societal support for nerve repair and included in AAOMS ParCare Guidelines can be leveraged to influence H&N societies Clinical Education Leadership Axogen has developed and executed on high quality national attending level professional education programs with proven post program adoption Clinical Evidence Independent clinical evidence with strong outcome data in benign mandible reconstruction and lingual nerve repair Direct Sales Channel Axogen has a large direct sales channel to service the highly concentrated market Oral Maxillofacial and Head & Neck 13

POSITIONED TO WIN Specialized Sales & Marketing Dedicated, deeply knowledgeable sales team enables effective surgeon development, support and market penetration Marketing expertise in the creation of strategies, tactics, tools, and resources support the sales process Established, predictable customer creation process Proven Patient Activation Strategy Axogen’s marketing team excels at translating complex medical information into patient-friendly content, raising awareness and driving demand for Resensation® Clinical Education Leadership A collaborative approach to training has resulted in surgeon advocacy, high adoption rates and strong customer loyalty Standardized, branded procedure 80%+ surgeon adoption after training Breast 14 25K+ monthly website visitors 3K+ monthly visitors to surgeon locator

POSITIONED TO WIN Clinical Education Leadership Extensive expertise in developing standardized surgical techniques and building comprehensive training courses to equip surgeons with the necessary skills and knowledge to successfully perform the procedures Nerve Repair Portfolio Axogen’s nerve repair portfolio has the potential to help surgeons address nerve protection and reconstruction needs in robotic assisted radical prostatectomy Patient Awareness & Activation Marketing team excels at executing campaigns that raise awareness of clinical problems and drives patient demand for new treatments 15 Prostate

Non-Covered Covered Societal support for Standard of Care designation achieved Non-Covered Covered Positive Avance coverage momentum continues as payers respond to Axogen’s educational efforts 86% 86% Expanded coverage fueled by Biologic approval in 2025 Strong clinical evidence Avance Medicare & Medicaid Lives Covered Since Q2 2025, 61.8 million lives have been added across Cigna, Elevance* and 10 BCBS regional plans (57.3mm private; 4.5mm Medicare Advantage)​ 16 Disclaimer: The information is derived from publicly available information and is for illustrative purposes only and is not authoritative. Coverage data are for informational purposes only and do not imply clinical or financial superiority. *Elevance covers Avance when: (1) the nerve gap is ≥5 mm and ≤ 25 mm, following resection; and (2) the repair is 24 weeks or less since the index injury or resection 1,2 1,2 Avance Commercial Lives Covered 1. Policy Reporter online portal for medical policy information [Dec 2025, 2. Health plan enrollment data provided by Managed Markets Insight & Technology, LLC [Sept 2025]

National Average2025 FACILITY PAYMENT In 2026, CMS Improved Facility Payments by Creating a New Outpatient Code Group The code for Allograft 64912 (Avance) is not specific to a clinical application and can therefore be applied to nerve repair in all anatomical locations CPT Code Descriptor C-APC Reimbursement Hospital Outpatient Reimbursement Ambulatory Surgery Center 64912 Allograft nerve repair 5432 $8,965 $6,157* +40% YoY +96% Since 2019 +35% YoY +221% Since 2019 National Average Disclaimer: The information is derived from publicly available information and is for illustrative purposes only and is not authoritative. 17 * Device intensive status achieved in 2020 New Level 3 Nerve Procedure Code increases reimbursement for hospitals and ASC’s

18 INNOVATION METRICS Avance Biologic License Approval 3 Active Development Projects Prostate Clinical Development 2022 2023 2024 2025 2026 2027 2028 + New Product Development Axoguard HA+ Nerve Protector® Avive+ Soft Tissue Matrix New Clinical Applications Resensation Implant NAC Prostate Our Nerve Care Roadmap to Provide Improved Benefit-to-Risk Profiles versus Existing Standards of Care Easy Coaptation Protection Expansion Therapeutic Reconstruction Additional New Clinical Applications

Our Clinical Evidence Investments in Support of Standard of Care Objectives Completed CHANGE Digital Nerve Pilot Study RECON ® Phase 3 RCT RALP-N Pilot Technique Feasibility and Outcomes REPOSE ® Post-Market Axoguard Nerve Cap RCT Underway Planned Establishing the Foundation Strengthening the Evidence Advancing Standard of Care Sensation-NOW ® Autologous Breast Neurotization Registry RANGER ® Real-World Registry REPOSE-XL ® Post-Market Axoguard Nerve Cap Case Series COVERED Post-Market Axoguard HA+ Protection Case Series Implant NAC-N Prospective Evidence in Breast Neurotization Mixed & Motor Nerve Level 1 Evidence: Avance vs. Autograft Protection Expansion Validating Nerve Protection Benefits Across New Applications Prostate Advancing Evidence in Cavernous Nerve Repair 19

Management Team with a Track Record of Success Michael Dale Chief Executive Officer and Board Director Marc Began Executive Vice President and General Counsel Lindsey Hartley Chief Financial Officer Erick DeVinney Chief Innovation Officer Jens Schroeder Kemp Chief Marketing Officer Ivica Ducic, M.D. Chief Medical Officer Craig Swandal Vice President, Operations Stacy Arnold Vice President of Product Development and Clinical Research Al Jacks Vice President of Quality Rick Ditto Vice President, Global Health Economics, Reimbursement & Policy Doris Quackenbush Vice President of Sales Jesse Bishop Vice President, Regulatory Prior Roles Include 20

Financial Overview 21

Accelerating Topline Drives Operational Leverage Accelerating Revenue Growth 22 Expanding EBITDA 2022 2023 2024 2025 2026 Q1 $61.5 $138.6 $159.0 $187.3 $225.2 ($22.6) ($25.6) ($15.5) $3.9 ($2.2) ($9.3) ($9.3) ($1.1) $19.8 $27.9 ($30.0) ($20.0) ($10.0) $0.0 $10.0 $20.0 $30.0 $40.0 EBITDA Adj-EBITDA* 2021 2022 2023 2024 2025 *Excludes non-cash stock-based compensation and litigation related costs 18.1% 5-year CAGR ($ in millions) $270.0* *Q1 2026 actual and full-year 2026 guidance ($ in millions)

Revenue growth of at least 20% or $270 million Gross margin of 74% to 76% 23 Free cash flow positive 2026 Guidance

Investment Highlights Big Market Opportunity $5.6B TAM with minimal current penetration 24 Clinical Leadership Unique comprehensive solution with strong evidence Multiple Growth Catalysts Four distinct market opportunities at different stages Reimbursement Tailwinds Expanding coverage and improving payment rates Scalable Infrastructure Proven commercial model ready to capture market share Financial Inflection Point Positive cashflow, expanding margins, accelerating growth

Thank you © 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation.

26

GRAPHIC — AXGN LOGO

GRAPHIC

Filename: axgn-20260428_g1.jpg · Sequence: 8

Binary file (30876 bytes)

Download axgn-20260428_g1.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 1

GRAPHIC

Filename: ex992axgn_q1earningsrele001.jpg · Sequence: 9

Binary file (87025 bytes)

Download ex992axgn_q1earningsrele001.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 2

GRAPHIC

Filename: ex992axgn_q1earningsrele002.jpg · Sequence: 10

Binary file (212504 bytes)

Download ex992axgn_q1earningsrele002.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 3

GRAPHIC

Filename: ex992axgn_q1earningsrele003.jpg · Sequence: 11

Binary file (58774 bytes)

Download ex992axgn_q1earningsrele003.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 4

GRAPHIC

Filename: ex992axgn_q1earningsrele004.jpg · Sequence: 12

Binary file (70055 bytes)

Download ex992axgn_q1earningsrele004.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 5

GRAPHIC

Filename: ex992axgn_q1earningsrele005.jpg · Sequence: 13

Binary file (88453 bytes)

Download ex992axgn_q1earningsrele005.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 6

GRAPHIC

Filename: ex992axgn_q1earningsrele006.jpg · Sequence: 14

Binary file (153079 bytes)

Download ex992axgn_q1earningsrele006.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 7

GRAPHIC

Filename: ex992axgn_q1earningsrele007.jpg · Sequence: 15

Binary file (103814 bytes)

Download ex992axgn_q1earningsrele007.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 8

GRAPHIC

Filename: ex992axgn_q1earningsrele008.jpg · Sequence: 16

Binary file (134386 bytes)

Download ex992axgn_q1earningsrele008.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 9

GRAPHIC

Filename: ex992axgn_q1earningsrele009.jpg · Sequence: 17

Binary file (62127 bytes)

Download ex992axgn_q1earningsrele009.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 10

GRAPHIC

Filename: ex992axgn_q1earningsrele010.jpg · Sequence: 18

Binary file (50840 bytes)

Download ex992axgn_q1earningsrele010.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 11

GRAPHIC

Filename: ex992axgn_q1earningsrele011.jpg · Sequence: 19

Binary file (77575 bytes)

Download ex992axgn_q1earningsrele011.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 12

GRAPHIC

Filename: ex992axgn_q1earningsrele012.jpg · Sequence: 20

Binary file (71737 bytes)

Download ex992axgn_q1earningsrele012.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 13

GRAPHIC

Filename: ex992axgn_q1earningsrele013.jpg · Sequence: 21

Binary file (68889 bytes)

Download ex992axgn_q1earningsrele013.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 14

GRAPHIC

Filename: ex992axgn_q1earningsrele014.jpg · Sequence: 22

Binary file (53985 bytes)

Download ex992axgn_q1earningsrele014.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 15

GRAPHIC

Filename: ex992axgn_q1earningsrele015.jpg · Sequence: 23

Binary file (30622 bytes)

Download ex992axgn_q1earningsrele015.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 16

GRAPHIC

Filename: ex992axgn_q1earningsrele016.jpg · Sequence: 24

Binary file (39386 bytes)

Download ex992axgn_q1earningsrele016.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 17

GRAPHIC

Filename: ex992axgn_q1earningsrele017.jpg · Sequence: 25

Binary file (82266 bytes)

Download ex992axgn_q1earningsrele017.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 18

GRAPHIC

Filename: ex992axgn_q1earningsrele018.jpg · Sequence: 26

Binary file (125481 bytes)

Download ex992axgn_q1earningsrele018.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 19

GRAPHIC

Filename: ex992axgn_q1earningsrele019.jpg · Sequence: 27

Binary file (101028 bytes)

Download ex992axgn_q1earningsrele019.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 20

GRAPHIC

Filename: ex992axgn_q1earningsrele020.jpg · Sequence: 28

Binary file (47308 bytes)

Download ex992axgn_q1earningsrele020.jpg

GRAPHIC — FIRST QUARTER FINANCIAL RESULTS PRESENTATION PAGE 21

GRAPHIC

Filename: ex992axgn_q1earningsrele021.jpg · Sequence: 29

Binary file (32068 bytes)

Download ex992axgn_q1earningsrele021.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 1

GRAPHIC

Filename: ex993axgn_corporateprese001.jpg · Sequence: 30

Binary file (107935 bytes)

Download ex993axgn_corporateprese001.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 2

GRAPHIC

Filename: ex993axgn_corporateprese002.jpg · Sequence: 31

Binary file (210255 bytes)

Download ex993axgn_corporateprese002.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 3

GRAPHIC

Filename: ex993axgn_corporateprese003.jpg · Sequence: 32

Binary file (72883 bytes)

Download ex993axgn_corporateprese003.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 4

GRAPHIC

Filename: ex993axgn_corporateprese004.jpg · Sequence: 33

Binary file (138510 bytes)

Download ex993axgn_corporateprese004.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 5

GRAPHIC

Filename: ex993axgn_corporateprese005.jpg · Sequence: 34

Binary file (97682 bytes)

Download ex993axgn_corporateprese005.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 6

GRAPHIC

Filename: ex993axgn_corporateprese006.jpg · Sequence: 35

Binary file (92258 bytes)

Download ex993axgn_corporateprese006.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 7

GRAPHIC

Filename: ex993axgn_corporateprese007.jpg · Sequence: 36

Binary file (190181 bytes)

Download ex993axgn_corporateprese007.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 8

GRAPHIC

Filename: ex993axgn_corporateprese008.jpg · Sequence: 37

Binary file (102533 bytes)

Download ex993axgn_corporateprese008.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 9

GRAPHIC

Filename: ex993axgn_corporateprese009.jpg · Sequence: 38

Binary file (108181 bytes)

Download ex993axgn_corporateprese009.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 10

GRAPHIC

Filename: ex993axgn_corporateprese010.jpg · Sequence: 39

Binary file (110094 bytes)

Download ex993axgn_corporateprese010.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 11

GRAPHIC

Filename: ex993axgn_corporateprese011.jpg · Sequence: 40

Binary file (129800 bytes)

Download ex993axgn_corporateprese011.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 12

GRAPHIC

Filename: ex993axgn_corporateprese012.jpg · Sequence: 41

Binary file (146521 bytes)

Download ex993axgn_corporateprese012.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 13

GRAPHIC

Filename: ex993axgn_corporateprese013.jpg · Sequence: 42

Binary file (118487 bytes)

Download ex993axgn_corporateprese013.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 14

GRAPHIC

Filename: ex993axgn_corporateprese014.jpg · Sequence: 43

Binary file (136708 bytes)

Download ex993axgn_corporateprese014.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 15

GRAPHIC

Filename: ex993axgn_corporateprese015.jpg · Sequence: 44

Binary file (107105 bytes)

Download ex993axgn_corporateprese015.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 16

GRAPHIC

Filename: ex993axgn_corporateprese016.jpg · Sequence: 45

Binary file (116797 bytes)

Download ex993axgn_corporateprese016.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 17

GRAPHIC

Filename: ex993axgn_corporateprese017.jpg · Sequence: 46

Binary file (119126 bytes)

Download ex993axgn_corporateprese017.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 18

GRAPHIC

Filename: ex993axgn_corporateprese018.jpg · Sequence: 47

Binary file (109484 bytes)

Download ex993axgn_corporateprese018.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 19

GRAPHIC

Filename: ex993axgn_corporateprese019.jpg · Sequence: 48

Binary file (118095 bytes)

Download ex993axgn_corporateprese019.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 20

GRAPHIC

Filename: ex993axgn_corporateprese020.jpg · Sequence: 49

Binary file (128218 bytes)

Download ex993axgn_corporateprese020.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 21

GRAPHIC

Filename: ex993axgn_corporateprese021.jpg · Sequence: 50

Binary file (42279 bytes)

Download ex993axgn_corporateprese021.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 22

GRAPHIC

Filename: ex993axgn_corporateprese022.jpg · Sequence: 51

Binary file (81536 bytes)

Download ex993axgn_corporateprese022.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 23

GRAPHIC

Filename: ex993axgn_corporateprese023.jpg · Sequence: 52

Binary file (60466 bytes)

Download ex993axgn_corporateprese023.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 24

GRAPHIC

Filename: ex993axgn_corporateprese024.jpg · Sequence: 53

Binary file (100716 bytes)

Download ex993axgn_corporateprese024.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 25

GRAPHIC

Filename: ex993axgn_corporateprese025.jpg · Sequence: 54

Binary file (30340 bytes)

Download ex993axgn_corporateprese025.jpg

GRAPHIC — CORPORATE PRESENTATION PAGE 26

GRAPHIC

Filename: ex993axgn_corporateprese026.jpg · Sequence: 55

Binary file (83287 bytes)

Download ex993axgn_corporateprese026.jpg

GRAPHIC — AXGN LOGO

GRAPHIC

Filename: image_0a.jpg · Sequence: 56

Binary file (30876 bytes)

Download image_0a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 58

v3.26.1

Cover

Apr. 28, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Apr. 28, 2026

Entity Registrant Name

AXOGEN, INC.

Entity Incorporation, State or Country Code

MN

Entity File Number

001-36046

Entity Tax Identification Number

41-1301878

Entity Address, Address Line One

13631 Progress Boulevard, Suite 400

Entity Address, City or Town

Alachua

Entity Address, State or Province

FL

Entity Address, Postal Zip Code

32615

City Area Code

386

Local Phone Number

462-6800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

AXGN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0000805928

Amendment Flag

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration